COMMENT

R&D

Cannabinoids receptors: popular preclinical target but banned in 137 countries

Cannabinoid receptors are currently the most popular targets for CNS in preclinical development, with 391 drugs tagged in total

insight

Europe reports the highest prevalence of chronic cough

comment

Could vaccine hesitancy impact hearing disorders?

Go to article: Home | Biosimilars set the stageGo to article: In this issueGo to article: ContentsGo to article: CSafeAPSGo to article: Mimotopes Company Insight Go to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: TripletreeGo to article: CommentGo to article: Cannabinoids receptors: popular preclinical target but banned in 137 countriesGo to article: Ozempic compensating for Wegovy’s supply shortage due to high demandGo to article: Manufacturing challenges set back progress of cell therapies in oncologyGo to article: Chinese transition to innovative pharma needs more investmentGo to article: DLBCL: a rapidly evolving treatment landscape with a crowded pipelineGo to article: Bio Image Systems Inc.Go to article: In DepthGo to article: Humira biosimilars set the stage for long-awaited 2023 US launchesGo to article: Expanding ketamine’s horizons for rare neurological disordersGo to article: The “Medical Bypass”: New drugs to strike obesityGo to article: Running low on comparators: drug shortages in oncology clinical trialsGo to article: ACT EU state of play: EMA’s headway to transform clinical trialsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-DecemberGo to article: EventsGo to article: Next issue